Asthma Trial, Recruiting NCT06535087 Sponsor: Wenjing Zhou Condition: Asthma
Back to Asthma

Asthma Trial, Recruiting

NCT06535087
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Children:

  • Children aged 5 to 16 years
  • Children who have been diagnosed with asthma, allergic rhinitis (hay fever), or both by a lung or allergy specialist, with symptoms lasting at least 4 weeks
  • Children whose parent or guardian has signed the consent form agreeing to take part
  • Children who are able to understand and fill out a questionnaire
  • Children who are patients (either visiting or admitted) at the Pediatrics Department of Renji Hospital in Shanghai

Parents or Caregivers:

  • The main caregiver of the child taking part in the trial
  • Caregivers who were present at the hospital on the day of the child's visit
  • Caregivers who have signed the consent form agreeing to take part
  • Caregivers who are able to understand and fill out a questionnaire

Who may not be able to join:

Children:

  • Children who are unlikely to follow the study requirements consistently
  • Children who are already receiving a specific allergy treatment called immunotherapy at another hospital
  • Children who are not able to read and complete the questionnaire on their own
  • Children who are unable to continue follow-up visits or have stopped their treatment

Parents or Caregivers:

  • Caregivers who do not wish to sign the consent form
  • Caregivers who are unable to complete the questionnaire due to health reasons or literacy level

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Wenjing Zhou, Renji Hospital, School of Medicine, Shanghai Jiaotong University

Phone: +31685281032

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Wenjing Zhou
Registry
ClinicalTrials.gov
Start date
20 July 2024
Est. completion
23 June 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Asthma control level for asthmatic children; Severity assessment of allergic rhinitis; EQ-5D-Y-3L for assessing health-related quality of life; EQ-VAS for assessing health-related quality of life; PAQLQ for assessing health-related quality of life in children with asthma; JRQLQ-No. 1 for assessing health-related quality of life in children with allergic rhinitis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov